A single-arm study to demonstrate the efficacy and safety of Privigen in the treatment of subjects with chronic inflammatory demyelinating polyneuropathy (CIDP)

Registry ID

EUCTR2009-017672-24

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

CSL Behring GmbH

Start date

2010-08-06

Completion date

2011-11-29

Last update

2026-08-16

Conditions

• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Summary

The objective of the study is to demonstrate the efficacy and safety of Privigen in subjects with CIDP.

Locations

• , , Belgium
• , , Finland

Related clinical trials

• Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
• CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
• Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP
• Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study

View on source registry